The others segment by type is estimated to lead the market growth during the forecast period.

According to a new market research study of “Asia Pacific Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type, Indication, Distribution Channel, and Country.” The Asia Pacific carbapenem-based antibiotics market is expected to reach US$ 1,506.07 million by 2028 from US$ 1,072.76 million in 2021; it is estimated to grow at a CAGR of 5.0% from 2021 to 2028. The report highlights trends prevailing in the Asia Pacific carbapenem-based antibiotics market and the factors driving market along with those that act as hindrances.

Generic versions are popular due to their availability and affordability. In addition, the expiry of patented carbapenem-based antibiotics has widen-up opportunities for generic drug manufacturers to enter the market with their cost-efficient drugs. The main focus of generic drug producers is to increase the reach of these drugs. Moreover, the shortage of antibiotics to treat bacterial infections is also one of the prime factors driving the market. The increased production of generic carbapenem-based antibiotics has increased drug availability in various low- and middle-income countries.

Generic versions of carbapenem drugs available in the market are ertapenem (Invanz), imipenem/cilastatin (Primaxin IM), doripenem (Doribax), and meropenem (Merrem). In addition, the growing number of generic players in the market is accelerating the production of generic drugs. Many Asian companies are engaged in developing active pharmaceutical ingredients (API), which are required to produce generic carbapenem-based antibiotics. In June 2021, JW Pharmaceutical, a South Korean company, announced it had completed production of its API for Ertapenem injection and shipped it to the US. The company plans to enter the global carbapenem antibiotic market in the coming years. It has also succeeded in developing its technology independently in Korea to produce Doripenem. Furthermore, the company plans to expand the sales of both API and finished drugs of Imipenem and Meropenem by exporting them to over 40 countries, including China and Japan. Therefore, accelerated generic drug production by the companies is driving the global carbapenem-based antibiotics market.

The Asia Pacific carbapenem-based antibiotics market, by type, is segmented into meropenem, doripenem, imipenem, tebipenem, and others. Based on indication, the Asia Pacific carbapenem-based antibiotics market has been segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. Based on distribution channel, the Asia Pacific carbapenem-based antibiotics market has been segmented into retail pharmacies, online pharmacies, and hospital pharmacies. Geographically, the Asia Pacific carbapenem-based antibiotics market is sub-segmented into China, India, Japan, South Korea, Australia and Rest of Asia Pacific.

ACS Dobfar S.p.A, Aurobindo Pharma Ltd, DAEWOONG PHARMACEUTICAL CO., LTD, Gland Pharma Limited, Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Savior Lifetec, Pfizer Inc., and Spero Therapeutics are among the leading companies operating in the Asia Pacific carbapenem-based antibiotics market.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com